These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30211927)

  • 21. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
    Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
    G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation.
    Steinberg BA; Washam JB
    Trends Cardiovasc Med; 2017 Nov; 27(8):567-572. PubMed ID: 28750830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of the non-vitamin K oral anticoagulants for atrial fibrillation.
    P Giugliano R
    Ther Adv Cardiovasc Dis; 2017 Mar; 11(3):77-79. PubMed ID: 28190378
    [No Abstract]   [Full Text] [Related]  

  • 27. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
    Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
    Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Eur Heart J; 2013 Jul; 34(27):2094-106. PubMed ID: 23625209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New oral anticoagulants for prophylaxis of stroke : Results of an expert conference on practical use in geriatric patients].
    Bahrmann P; Harms F; Schambeck CM; Wehling M; Flohr J
    Z Gerontol Geriatr; 2016 Jul; 49(5):460-1. PubMed ID: 27357589
    [No Abstract]   [Full Text] [Related]  

  • 30. Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants.
    Massaro A; Giugliano RP; Norrving B; Oto A; Veltkamp R
    Int J Stroke; 2016 Dec; 11(9):950-967. PubMed ID: 27703066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
    Saji N; Kimura K; Tateishi Y; Fujimoto S; Kaneko N; Urabe T; Tsujino A; Iguchi Y;
    J Thromb Thrombolysis; 2016 Nov; 42(4):453-62. PubMed ID: 27207691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do the current atrial fibrillation guidelines for stroke prevention need to be changed with the availability of new data on the new oral anticoagulants?
    Foley J; Lip GY
    Int J Clin Pract; 2012 May; 66(5):422-4. PubMed ID: 22512602
    [No Abstract]   [Full Text] [Related]  

  • 33. [Antithrombotic treatment of patients with valvular atrial fibrillation].
    Bovin A; Christensen TD; Grove EL
    Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-vitamin K antagonist oral anticoagulants for heart diseases].
    Kondratieva TB; Popova LV; Bokarev IN
    Ter Arkh; 2017; 89(9):120-127. PubMed ID: 29039841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.
    Dalal J; Bhave A; Oomman A; Vora A; Saxena A; Kahali D; Poncha F; Gambhir DS; Chaudhuri JR; Sinha N; Ray S; Iyengar SS; Banerjee S; Kaul U;
    Indian Heart J; 2015 Dec; 67 Suppl 2(Suppl 2):S13-34. PubMed ID: 26688149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Should all patients with atrial fibrillation and CHA2DS2-VASc score 1 receive oral anticoagulation?].
    Di Pasquale G; Zagnoni S
    G Ital Cardiol (Rome); 2015 Nov; 16(11):608-12. PubMed ID: 26571473
    [No Abstract]   [Full Text] [Related]  

  • 38. Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation.
    Suwa M; Morii I; Kino M
    Europace; 2021 Oct; 23(10):1686. PubMed ID: 34549782
    [No Abstract]   [Full Text] [Related]  

  • 39. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey.
    Larsen TB; Potpara T; Dagres N; Proclemer A; Sciarrafia E; Blomström-Lundqvist C;
    Europace; 2015 May; 17(5):819-24. PubMed ID: 25926476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.
    Xiong Q; Lau YC; Lip GY
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):937-48. PubMed ID: 25797167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.